Overview
- Remedy said on Tuesday that Q2 revenue fell 40% year‑on‑year to €10.2 million and H1 revenue dropped 23.1% to €23.3 million while EBITDA remained marginally positive.
- The company blamed the decline on a tough comparison with Q2 2025 and an increase in promotional spending, noting other operating expenses rose by about €1.7 million because marketing for CONTROL Resonant was ramped up.
- CONTROL Resonant has passed 1.5 million wishlists and—according to Remedy’s internal data—ranked among the top three pre‑ordered PS5 titles in the US, Germany and Brazil as pre‑orders opened, with a worldwide launch set for September 24, 2026.
- Remedy reported catalogue strength with Alan Wake 2 exceeding three million lifetime sales, and it counted development fees from Resonant and the Max Payne 1 & 2 remake among quarterly revenue while confirming three active projects and a new title now production‑ready.
- The studio enters the launch window with €29.6 million in cash and liquid investments, a net cash position of €11.8 million, and a maintained full‑year outlook that ties near‑term recovery and profitability to Resonant’s commercial performance in a crowded September release schedule.